Hims & Hers Health, Inc. (NYSE:HIMS) Shares Acquired by Principal Financial Group Inc.

Principal Financial Group Inc. grew its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 370.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,365,769 shares of the company’s stock after acquiring an additional 1,075,355 shares during the period. Principal Financial Group Inc. owned about 0.63% of Hims & Hers Health worth $33,024,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also modified their holdings of HIMS. CWM LLC grew its stake in shares of Hims & Hers Health by 21.4% in the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after acquiring an additional 1,054 shares in the last quarter. Creative Planning grew its stake in shares of Hims & Hers Health by 18.1% during the third quarter. Creative Planning now owns 25,925 shares of the company’s stock worth $478,000 after purchasing an additional 3,979 shares in the last quarter. International Assets Investment Management LLC acquired a new position in shares of Hims & Hers Health during the third quarter worth $6,790,000. Dakota Wealth Management acquired a new position in shares of Hims & Hers Health during the third quarter worth $245,000. Finally, Lake Street Advisors Group LLC grew its stake in shares of Hims & Hers Health by 42.2% during the third quarter. Lake Street Advisors Group LLC now owns 67,366 shares of the company’s stock worth $1,241,000 after purchasing an additional 20,000 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Stock Down 26.1 %

NYSE HIMS opened at $49.10 on Friday. The stock has a market capitalization of $10.73 billion, a P/E ratio of 111.58 and a beta of 1.35. Hims & Hers Health, Inc. has a 52-week low of $9.25 and a 52-week high of $72.98. The firm has a 50-day moving average price of $35.05 and a 200 day moving average price of $25.70.

Insider Buying and Selling

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 101,993 shares of the company’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $29.62, for a total transaction of $3,021,032.66. Following the transaction, the chief financial officer now directly owns 109,392 shares in the company, valued at approximately $3,240,191.04. This represents a 48.25 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Andrew Dudum sold 128,127 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the transaction, the chief executive officer now owns 97,687 shares in the company, valued at $5,692,221.49. The trade was a 56.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 1,184,611 shares of company stock valued at $40,338,442 over the last ninety days. Corporate insiders own 17.71% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have issued reports on HIMS. Citigroup downgraded shares of Hims & Hers Health from a “neutral” rating to a “sell” rating and upped their price objective for the company from $24.00 to $25.00 in a research note on Friday, January 10th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research note on Wednesday, November 6th. Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a “buy” rating in a research note on Wednesday. TD Cowen restated a “buy” rating and issued a $28.00 price objective on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Finally, Needham & Company LLC upped their target price on shares of Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a report on Monday, January 6th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Hims & Hers Health has an average rating of “Hold” and an average target price of $28.53.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.